Cost Analysis and Value of Utility for Patients in Haemodialysis with Carbonic Cevelamer Therapy

Authors

  • Dwi Putri Safnurbaiti Program Studi Farmasi, Fakultas Kesehatan Universitas Hamzanwadi
  • Tri Murti Andayani Fakultas Farmasi UGM Jogjakarta
  • Fredie Irijanto RS UGM Jogjakarta

DOI:

https://doi.org/10.30649/obj.v1i2.12

Keywords:

analisis biaya, EQ-5D-%L, nilai utilitas, hemodialisa, sevelamer karbonat

Abstract

Sevelamer karbonat merupakan alternatif lain sebagai terapi pengikat fosfat yang
diberikan kepada pasien hemodialisa selain CaCO3. Sevelamer karbonat dapat
menurunkan kadar fosfat, mengurangi kejadian kalsifikasi vaskular dan mortalitas yang
secara langsung berdampak pada perbaikan kualitas hidup pasien hemodialisa, namun
harga sevelamer karbonat lebih mahal dibandingkan dengan CaCO3. Penelitian ini
bertujuan untuk mengetahui gambaran biaya yang diperlukan untuk terapi sevelamer
karbonat dan nilai utilitas pasien hemodialisa yang menggunakan terapi sevelamer
karbonat di RS UGM Yogyakarta.
Penelitian dilakukan secara prospektif selama 8 minggu di RS UGM Yogyakarta
pada bulan Oktober-November 2016. Desain penelitian adalah quasi eksperimental
dengan “pretest posttest design with control group”. Kelompok eksperimental adalah
sevelamer karbonat dan kontrol adalah CaCO3. Pengukuran health related quality of life
(HRQOL) pasien hemodialisa salah satunya dengan mengukur utilitas pasien hemodialisa
dengan kuesioner EQ-5D-5L pada awal (pre) dan akhir (post) penelitian. Analisis biaya
dilihat berdasarkan perspektif rumah sakit dengan menghitung total direct medical cost.
Jumlah total responden dalam penelitian ini adalah 37 pasien yang terdiri atas 16
pasien kelompok eksperimental dan 21 pasien kelompok kontrol. Rata-rata biaya yang
diperlukan pasien hemodialisa dengan sevelamer karbonat untuk menangani kondisi
gangguan mineral dan tulang adalah sebesar Rp 2.999.188,75±167.920,75 per pasien
selama 8 minggu terapi. Nilai utilitas dan skor EQ-5D VAS baseline pasien hemodialisa
yang diberikan sevelamer karbonat adalah masing-masing 0,91±0,13 dan 75,93±9,34, dan
di akhir penelitian (posttes) terdapat perubahan nilai utilitas dan skor EQ-5D VAS sebesar
0,93±0,08 dan 77,44±11,12. Hasil uji statistik menunjukkan bahwa perubahan nilai
utilitas dan skor EQ-5D VAS pasien hemodialisa yang diberikan sevelamer karbonat
antara awal (pre) dan akhir penelitian (posttes) adalah menunjukkan tidak berbeda
bermakna (p>0,05).

References

Anees, M., Hameed, F., Mumtaz, A., Ibrahim, M., dan Saeed Khan, M.N., 2011. Dialysisrelated factors affecting quality of life in patients on hemodialysis. Iranian

Journal of Kidney Diseases, 5: 9–14.

Block, G.A., 2004. Mineral Metabolism, Mortality, and Morbidity in Maintenance

Hemodialysis. Journal of the American Society of Nephrology, 15: 2208–2218.

Chiu, Y.-W., Teitelbaum, I., Misra, M., de Leon, E.M., Adzize, T., dan Mehrotra, R.,

Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in

Maintenance Dialysis Patients. Clinical Journal of the American Society of

Nephrology, 4: 1089–1096.

Coladonato, J.A., 2005. Control of Hyperphosphatemia among Patients with ESRD.

Journal of the American Society of Nephrology, 16: S107–S114.

Di Iorio, B., Molony, D., Bell, C., Cucciniello, E., Bellizzi, V., Russo, D., dkk., 2013.

Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results

of an Open-Label 24-Month Randomized Clinical Trial. American Journal of

Kidney Diseases, 62: 771–778.

Endarti, D., Riewpaiboon, A., Thavorncharoensap, M., Praditsitthikorn, N., Hutubessy,

R., dan Kristina, S.A., 2015. Evaluation of Health-Related Quality of Life among

Patients with Cervical Cancer in Indonesia. Asian Pacific Journal of Cancer

Prevention, 16: 3345–3350.

Faridah, A., Jamaiyah, H., Goh, A., Soraya, A., dan others, 2010. The validation of the

EQ-5D in Malaysian dialysis patients. Med J Malaysia, 65: 114–119.

Fröschl, B., Brunner-Ziegler, S., Hiebinger, C., Wimmer, A., dan Zsifkovits, J., 2009.

Effectiveness and cost-efficiency of phosphate binders in hemodialysis. GMS

health technology assessment, 5: .

Galante, J., Augustovski, F., Colantonio, L., Bardach, A., Caporale, J., Marti, S. G., dkk.,

Estimation and comparison of EQ-5D health states’ utlity weights for

pneumonococcal and human papillomavirus disease in Argentina, Chile, and the

United Kingdom. Value in Health: The Journal of the International Society for

Pharmacoeconomics and Outcomes Research, 14: S60-S64.

Gerogianni, S.K. dan Babatsikou, F.P., 2014. Psychological Aspects in Chronic Renal

Fail. Health science journal, 8: .

Grinfeld, J., Inaba, A., dan Hutchison, A.J., 2010. Update and critical appraisal of

sevelamer in the management of chronic renal failure. Open Access Journal of

Urology, 2: 161–170.

Huybrechts, K.F., Caro, J.J., Wilson, D.A., dan O’Brien, J.A., 2005. Health and Economic

Consequences of Sevelamer Use for Hyperphosphatemia in Patients on

Hemodialysis. Value in Health, 8: 549–561.

Javanbakht, M., Abolhasani, F., Mashayekhi, A., Baradaran, H.R., dan Jahangiri noudeh,

Y., 2012. Health Related Quality of Life in Patients with Type 2 Diabetes Mellitus

in Iran: A National Survey. PLoS ONE, 7: .

Jhita, T., Petrou, S., Gumber, A., Szczepura, A., Raymond, N.T., dan Bellary, S., 2014.

Ethnic differences in health related quality of life for patients with type 2 diabetes.

Health and Quality of Life Outcomes, 12: 83.

Katayama, A., Miyatake, N., Nishi, H., Uzike, K., Sakano, N., Hashimoto, H., dkk., 2014.

Evaluation of physical activity and its relationship to health-related quality of life

in patients on chronic hemodialysis. Environmental Health and Preventive

Medicine, 19: 220–225.

Lahana, E., dan Niakas, D., 2013. Investigating Differences in Health-Related Quality of

Life of Greeks and Albanian Immigrants with the Generic EQ-5D Questionnaire.

BioMed Research International, 2013.

Liem, Y.S., Bosch, J.L., dan Myriam Hunink, M.G., 2008. Preference-Based Quality of

Life of Patients on Renal Replacement Therapy: A Systematic Review and MetaAnalysis. Value in Health, 11: 733–741.

Matsushita, K., Sato, K., Unagami, K., Nitta, K., dan Tago, K., 2014. Effect of Sevelamer

Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients.

International Journal of Clinical Medicine, 05: 1320–1327.

Nadin, C., 2004. Sevelamer as a phosphate binder in adult hemodialysis patients: an

evidence-based review of its therapeutic value. Core evidence, 1: 43–63.

Nurchayati, S., 2010. 'Analisis Faktor-Faktor Yang Berhubungan dengan Kualitas Hidup

Pasien Penyakit Ginjal Kronik yang Menjalani Hemodialisis di Rumah Sakit

Islam Fatimah Cilacap dan Rumah Sakit Umum Banyumas', , Tesis, . Universitas

Indonesia, Jakarta.

Pattanaphesaj, J., 2014. 'Health-Related Quality of Life Measure (EQ-5D-5L) :

Measurement Property Testing and Its Preference-Based Score in Thai

Population', , Doctoral Dissertation, . Mahidol University, Thailand.

Pierce, D., Hossack, S., Poole, L., Robinson, A., Van Heusen, H., Martin, P., dkk., 2011.

The effect of sevelamer carbonate and lanthanum carbonate on the

pharmacokinetics of oral calcitriol. Nephrology Dialysis Transplantation, 26:

–1621.

Price, S.A. dan Wilson, L.M., 2006. Patofisiologi Konsep Klinis Proses-Proses Penyakit,

Edisi 6. ed. Penerbit Buku Kedokteran EGC, Jakarta.

Saffari, M., Pakpour, A.H., Naderi, M.K., Koenig, H.G., Baldacchino, D.R., dan Piper,

C.N., 2013. Spiritual coping, religiosity and quality of life: a study on Muslim

patients undergoing haemodialysis. Nephrology (Carlton, Vic.), 18: 269–275.

Sakthong, P. dan Kasemsup, V., 2012. Health Utility Measured with EQ-5D in Thai

Patients Undergoing Peritoneal Dialysis. Value in Health, 15: S79–S84.

Seica, A., Segall, L., Verzan, C., Văduva, N., Madincea, M., Rusoiu, S., dkk., 2009.

Factors affecting the quality of life of haemodialysis patients from Romania: a

multicentric study. Nephrology Dialysis Transplantation, 24: 626–629.

Shaheen, F.A., Akeel, N.M., Badawi, L.S., dan Souqiyyeh, M.Z., 2004. Efficacy and

safety of sevelamer. Comparison with calcium carbonate in the treatment of

hyperphosphatemia in hemodialysis patients. Saudi medical journal, 25: 785–791.

Wasserfallen, J.-B., Halabi, G., Saudan, P., Perneger, T., Feldman, H.I., Martin, P.-Y.,

dkk., 2004. Quality of life on chronic dialysis: comparison between haemodialysis

and peritoneal dialysis. Nephrology Dialysis Transplantation, 19: 1594–1599.

Yang, F., Griva, K., Lau, T., Vathsala, A., Lee, E., Ng, H.J., dkk., 2015. Health-related

quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore.

Quality of Life Research, 24: 2163–2171.

Zyoud, S.H., Daraghmeh, D.N., Mezyed, D.O., Khdeir, R.L., Sawafta, M.N., Ayaseh,

N.A., dkk., 2016. Factors affecting quality of life in patients on haemodialysis: a

cross-sectional study from Palestine. BMC Nephrology, 17:

Published

2018-07-02

How to Cite

Safnurbaiti, D. P., Andayani, T. M., & Irijanto, F. (2018). Cost Analysis and Value of Utility for Patients in Haemodialysis with Carbonic Cevelamer Therapy. Oceana Biomedicina Journal, 1(2), 79–89. https://doi.org/10.30649/obj.v1i2.12